Login / Signup

Susceptibility evaluation of novel beta-lactam/beta-lactamase inhibitor combinations against carbapenem-resistant Klebsiella pneumoniae from bloodstream infections in hospitalized patients in Brazil.

Camila Mörschbächer WilhelmLaura Czerkster AntochevisCibele Massotti MagagninBeatriz ArnsTarsila VieceliDariane Castro PereiraLarissa LutzÂndrea Celestino de SouzaJéssica Nesello Dos SantosRafaela Ramalho GuerraGregory S MedeirosLucas SantoroDiego R FalciMaria Helena RigattoAfonso Luís BarthAndreza Francisco MartinsAlexandre Prehn Zavascki
Published in: Journal of global antimicrobial resistance (2024)
. KPC-producing isolates demonstrated susceptibility rates above 94 % for all BLBLIs. Two isolates with resistance to meropenem/vaborbactam demonstrated a Gly and Asp duplication at the porin OmpK36 as well as a truncated OmpK35. All NDM-producing isolates, including KPC and NDM coproducers, demonstrated susceptibility rates to ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam of 0 %, 9.1-21.1 % and 9.1-26.3 %, respectively. Five NDM-producing isolates that presented susceptibility to BLBLIs also had porin alterations CONCLUSIONS: This study showed that, although high susceptibility rates to BLBLIs were found, KPC-2 isolates were able to demonstrate resistance probably as a result of porin mutations. Additionally, NDM-1 isolates showed susceptibility to BLBLIs in vitro.
Keyphrases
  • klebsiella pneumoniae
  • multidrug resistant
  • escherichia coli
  • gram negative
  • genetic diversity